Innovating Works

PAPWORTH HOSPITAL NHS FOUNDATION TRUST

A stranger
RITA-MI 2: Rituximab in patients with acute myocardial infarction a phase 2 placebo controlled randomised clin... PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un H2020: H2020-SC1-BHC-2018-2020 RITA-MI 2 will assess the impact of a novel therapeutic strategy targeting patients’ immune response on the recovery of heart function after...
2021-01-18 - 2026-05-31 | financed
Track and Know: Big Data for Mobility Tracking Knowledge Extraction in Urban Areas PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un H2020: H2020-ICT-2016-2017 Track&Know will research, develop and exploit a new software framework that aims at increasing the efficiency of Big Data applications in th...
2017-11-21 - 2020-12-31 | financed
RITA-MI: Rituximab in Acute Myocardial Infarction PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un H2020: ERC-2015-PoC Cardiovascular diseases (CVD) represent a major cause of morbidity and mortality. The best current therapy reduces CV risk by only 25-30% an...
2016-02-21 - 2018-08-31 | financed
IABC PROGRAMME: iABC Programme PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un FP6: Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
2015-08-01 - 2021-12-31 | financed
CFMATTERS: Cystic Fibrosis Microbiome determined Antibiotic Therapy Trial in Exacerbations Results Stratified. PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un FP7: Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is...
financed
IABC PROGRAMME: iABC Programme PAPWORTH HOSPITAL NHS FOUNDATION TRUST participó en un FP7: Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
financed
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.